355 related articles for article (PubMed ID: 31612108)
1. New Horizons in
Yang H; Liang SQ; Schmid RA; Peng RW
Front Oncol; 2019; 9():953. PubMed ID: 31612108
[TBL] [Abstract][Full Text] [Related]
2. KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Ferrer I; Zugazagoitia J; Herbertz S; John W; Paz-Ares L; Schmid-Bindert G
Lung Cancer; 2018 Oct; 124():53-64. PubMed ID: 30268480
[TBL] [Abstract][Full Text] [Related]
3. Targeting
Uras IZ; Moll HP; Casanova E
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560574
[TBL] [Abstract][Full Text] [Related]
4. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.
Shu CL; Liu YL
Cancer Manag Res; 2022; 14():3485-3492. PubMed ID: 36561983
[TBL] [Abstract][Full Text] [Related]
5. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
6. Current therapy of KRAS-mutant lung cancer.
Ghimessy A; Radeczky P; Laszlo V; Hegedus B; Renyi-Vamos F; Fillinger J; Klepetko W; Lang C; Dome B; Megyesfalvi Z
Cancer Metastasis Rev; 2020 Dec; 39(4):1159-1177. PubMed ID: 32548736
[TBL] [Abstract][Full Text] [Related]
7. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
[TBL] [Abstract][Full Text] [Related]
8. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
[No Abstract] [Full Text] [Related]
9. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
11. Molecular Signatures of
Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
[TBL] [Abstract][Full Text] [Related]
12. Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Aredo JV; Padda SK
Curr Treat Options Oncol; 2018 Jun; 19(8):43. PubMed ID: 29951788
[TBL] [Abstract][Full Text] [Related]
13. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
14. Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
Kordiak J; Szemraj J; Grabska-Kobylecka I; Bialasiewicz P; Braun M; Kordek R; Nowak D
J Cancer Res Clin Oncol; 2019 Jan; 145(1):241-251. PubMed ID: 30368666
[TBL] [Abstract][Full Text] [Related]
15. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
17. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup.
Xie M; Xu X; Fan Y
Front Oncol; 2021; 11():672612. PubMed ID: 34012925
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
19. Non-genetic adaptive resistance to KRAS
Ning W; Marti TM; Dorn P; Peng RW
Front Oncol; 2022; 12():1004669. PubMed ID: 36483040
[TBL] [Abstract][Full Text] [Related]
20. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT; Byers LA; Kim ES; Saintigny P; Lee JJ; Blumenschein GR; Tsao A; Liu S; Larsen JE; Wang J; Diao L; Coombes KR; Chen L; Zhang S; Abdelmelek MF; Tang X; Papadimitrakopoulou V; Minna JD; Lippman SM; Hong WK; Herbst RS; Wistuba II; Heymach JV; Powis G
J Natl Cancer Inst; 2012 Feb; 104(3):228-39. PubMed ID: 22247021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
